FY2022 EPS Estimates for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Cut by HC Wainwright – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Get Rating) – Analysts at HC Wainwright decreased their FY2022 EPS estimates for shares of Sol-Gel Technologies in a report issued on Monday, November 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.58) per share for the year, down from their previous forecast of ($0.35). HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Sol-Gel Technologies’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q4 2022 earnings at ($0.18) EPS, Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at ($0.29) EPS, Q3 2023 earnings at ($0.20) EPS, Q4 2023 earnings at ($0.08) EPS and FY2023 earnings at ($0.83) EPS.
Several other research firms have also recently issued reports on SLGL. Jefferies Financial Group started coverage on shares of Sol-Gel Technologies in a research note on Friday, October 21st. They issued a “hold” rating and a $5.50 target price for the company. Raymond James decreased their target price on shares of Sol-Gel Technologies from $16.00 to $13.00 and set a “strong-buy” rating for the company in a research note on Friday, November 11th.
Sol-Gel Technologies Price Performance
SLGL opened at $4.88 on Wednesday. The firm has a fifty day moving average price of $5.13 and a 200 day moving average price of $5.43. Sol-Gel Technologies has a 1 year low of $3.94 and a 1 year high of $9.19. The stock has a market cap of $112.76 million, a P/E ratio of 23.21 and a beta of 1.34.
Institutional Investors Weigh In On Sol-Gel Technologies
Several institutional investors and hedge funds have recently added to or reduced their stakes in SLGL. MYDA Advisors LLC purchased a new stake in Sol-Gel Technologies in the 3rd quarter worth $353,000. Raymond James & Associates increased its holdings in Sol-Gel Technologies by 25.4% in the 1st quarter. Raymond James & Associates now owns 47,492 shares of the company’s stock worth $350,000 after acquiring an additional 9,631 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Sol-Gel Technologies by 349.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,643 shares of the company’s stock worth $28,000 after acquiring an additional 4,387 shares in the last quarter.
Sol-Gel Technologies Company Profile
(Get Rating)
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.
Read More
- Get a free copy of the StockNews.com research report on Sol-Gel Technologies (SLGL)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sol-Gel Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sol-Gel Technologies wasn’t on the list.
While Sol-Gel Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.